Satya Das, MD, MSCI, on the Design of a Study of PRRT in Patients With Well-Differentiated NETs

The expert in hematology/oncology spoke about the study which evaluated the use of peptide receptor radionuclide therapy in patients with well-differentiated neuroendocrine tumors.

Of patients with well-differentiated neuroendocrine tumors (WD-NETs) who were treated with 3 to 4 doses of peptide receptor radionuclide therapy (PRRT), those with a lower clinical score experienced better progression-free survival (PFS) with treatment when compared against those with a higher clinical score, according to results from a study presented at the 2021 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancer Symposium.

Of note, this difference in PFS was not observed in patients who did not receive PRRT, indicating there is a predictive utility of clinical score for patients with WD-NETs receiving PRRT with lutetium Lu 177 dotatate (Lutathera).

In an interview with CancerNetwork®, Satya Das, MD, MSCI, assistant professor of Medicine in the department of Medicine of the division of Hematology/Oncology at Vanderbilt University Medical Center, discussed the design of the study.

Transcription:

There’s a lot of uncertainty as to when patients with well-differentiated NETs should get Lutathera or treatment with [peptide receptor radionuclide therapy; PRRT]. The focus of our study was to actually assess and look for answers. It was a cohort analysis that we did. And we looked at 146 patients, 122 at Vanderbilt Ingram Cancer Center and 24 from Rush Medical Center. We had a total of 146 patients included in this cohort.

Reference:

Das S, Du L, Schad A, et al. A clinical score (CS) for patients with well-differentiated neuroendocrine tumors (WD NETs) under consideration for peptide receptor radionuclide therapy (PRRT) with Lu 177-dotatate. J Clin Oncol. 2021;39(suppl 3). Abstract: 363.